The present study reports about new solid lipid nanoparticle assemblies (SLNas) loaded with rifampicin (RIF) surface-decorated with novel mannose derivatives, designed for anti-tuberculosis (TB) inhaled therapy by dry powder inhaler (DPI). Mannose is considered a relevant ligand to achieve active drug targeting being mannose receptors (MR) overexpressed on membranes of infected alveolar macrophages (AM), which are the preferred site of Mycobacterium tuberculosis. Surface decoration of SLNas was obtained by means of newly synthesized functionalizing compounds used as surfactants in the preparation of carriers. SLNas were fully characterized in vitro determining size, morphology, drug loading, drug release, surface mannosylation, cytotoxicity, macrophage internalization extent and ability to bind MR, and intracellular RIF concentration. Moreover, the influence of these new surface functionalizing agents on SLNas aerodynamic performance was assessed by measuring particle respirability features using next generation impactor. SLNas exhibited suitable drug payload, in vitro release, and more efficient ability to enter macrophages (about 80%) compared to bare RIF (about 20%) and to non-functionalized SLNas (about 40%). The involvement of MR-specific binding has been demonstrated by saturating MR of J774 cells causing a decrease of RIF intracellular concentration of about 40%. Furthermore, it is noteworthy that the surface decoration of particles produced a poor cohesive powder with an adequate respirability (fine particle fraction ranging from about 30 to 50%). Therefore, the proposed SLNas may represent an encouraging opportunity in a perspective of an efficacious anti-TB inhaled therapy.
Introduction
Macrophages are one of the primary sensors detecting endogenous danger signals that are present in the debris of necrotic cells through toll-like, intracellular pattern-recognition, interleukin-1, and mannose (MR) receptors [1] . MR recognize several microorganisms owing to their mannan-coated cell wall, such as Mycobacterium tuberculosis, Streptococcus pneumonia, Yersinia pestis, Candida albicans, Pneumocystis carinii, Cryptococcus neoformans, and Leishmania [2] .
The lungs, with their large surface area, are constantly exposed to microbes and particles entering by the airways [3] . Therefore, alveolar macrophages (AM) are unique cells with increased phagocytic ability that is due mainly to MR activity. In fact, surfactant protein A, the major component of lung surfactant, interacts with human macrophages and upregulates the surface expression of MR during an infection [4] . AM constitute the site of pathogen infection and consequently represent the target of several drugs and drug delivery systems [5] . One of the advantages of using particulate carriers lies in the possibility to insert at their surface molecules that recognize specific receptors on the targeted site to facilitate their internalization, such as mannose [6] . Moreover, MRmediated pathway is influenced by the relative ligand density of particle surface [7] . Mannosylated carriers have been demonstrated to be efficiently phagocytosed by AM, thus able to deliver a high drug payload in comparison to non-mannosylated formulations [8] [9] [10] [11] [12] . A restricted number of researchers explored the targeting to MR using different drug delivery systems to promote macrophage uptake in the treatment of tuberculosis (TB). Indeed, solid lipid nanoparticles or nanostructured lipid carriers modified by stearylamine for attaching mannose on the surface, mannosylated gelatin nanoparticles encapsulating isoniazid, and polymeric micelles surface-decorated with chitosan combined with hydrolyzed galactomannan were developed [12] [13] [14] [15] [16] .
The inhalation route, widely used for local or systemic treatments of other pathologies [17] , appears the most promising drug entry to reach promptly AM and maximize drug concentration at the primary site of TB infection. The major criticism in inhalation therapy is related to the carrier difficulty to reach the alveolar region, overstepping the upper respiratory tract. Among the different strategies improving respirability, surface particle modification using additives, hydrophobic components, or creation of corrugate particles were investigated [18] . The employment of additives has proved to reduce the forces between particulate carriers and hence promote de-aggregation during aerosolization. For this purpose, both sugars (lactose, trehalose), aminoacids (leucine, phenylalanine, glycine, alanine, isoleucine), polymers (PVA, PVP), and dipalmitoylphosphatidylcholine were used [19] [20] [21] [22] . In particular, leucine is a hydrophobic aminoacid that reduces particle contact area and consequently particle cohesion [21, 23] . Moreover, surface hydrophobicity avoids moisture adsorption and cohesion between particles. Indeed, sodium stearate provided protection from the environmental humidity of drug particles determining a superior stability and improved aerosol performance [24] as also recently confirmed by reference [25] . In the specific case of inhaled dry powders based on drugs loaded into carriers, the absence of formulation additives represents an advantage intended to minimize the powder mass to be introduced in dry powder inhaler (DPI) capsules and increase the efficacy of drug doses.
Our previous work was addressed to the study of solid lipid nanoparticle assemblies (SLNas) loaded with rifampicin (RIF) for an inhalation therapy against TB using DPI device [26] . Afterwards, the SLNas surface was decorated without chemical reactions using methyl mannopyranoside (MP), a functionalizing agent that required the combination with a surfactant during SLNas production. Although the presence of MP caused favorable physical properties and an improvement of the internalization rate by macrophages, respirability was impaired by the particle cohesiveness due to MP hydroxyl groups [27] . The aim of the work was the production and characterization of newly developed surface-decorated SLNas loaded with RIF. Four novel mannosylated derivatives having different hydrophilic/lipophilic balance conferring surfactant properties were synthesized for SLNas surfacedecoration in order to improve the final DPI product quality. In particular, the influence of fatty acids bearing different carbon chains employed in the synthesis of the functionalizing agents on the respirability profile and macrophage internalization was assessed.
Material and methods

Materials
For SLNas preparation, palmitic acid and sodium lauryl sulfate (SLS) were purchased from Fluka Chemie (Buchs, Switzerland), cholesteryl myristate, sodium taurocholate (ST), and methyl α-D-mannopyranoside (MP) from TCI Europe (Zwijndrecht, Belgium). Rifampicin (RIF) was a gift from Sanofi (Brindisi, Italy). For SLNas characterization, simulated lung fluid (SLF) at pH 7.4 was used [28] . The internal standard (IS) methyl parahydroxybenzoate was purchased from Carlo Erba Reagenti (Milan, Italy). For the cytotoxicity and cell internalization investigations, J774 murine macrophage cell line was from IZSLER (Brescia, Italy), cell culture reagents Dulbecco's Modified Eagle's Medium (DMEM) with high glucose, L-glutamine, fetal bovine serum (FBS), penicillin-streptomycin (P/S), non-essential amino acids (NEAA), and phosphate-buffered saline (PBS) from EuroClone (Milan, Italy), D-mannose from VWR International (Milan, Italy), Nile Red from Sigma-Aldrich Italia (Milan, Italy), Hoechst 33342, and Lysotracker green stain were purchased from ThermoFisher (Monza, Italy). All the other chemicals were of analytical grade.
Synthesis of functionalizing agents
The compounds P1, P2, P3, and P4 were synthesized as described in Fig. 1 . The starting material 2,3,4,6-tetra-Oacetyl-1-(2-aminoethyl)-α-D-mannose (5) was synthesized from D-mannose in three steps. The appropriate C8, C12, C14, and C16 carboxylic acids were conjugated to (5) by Fig. 1 Synthesis, structure of compounds (P1-P4), and their hydrophilic/ l i p o p h i l i c b a l a n c e ( H L B ) . W S C , 1 -e t h y l -3 -( 3 -dimethylaminopropyl)carbodiimide; HOBt, 1-hydroxybenzotriazole means of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (WSC) in the presence of 1-hydroxybenzotriazole (HOBt); then, compounds (1) (2) (3) (4) were deprotected by treatment of sodium methoxide in methanol under Zemplen conditions (data are given in supplementary information).
SLNas preparation
SLNas were prepared by the melt emulsification technique followed by freeze-drying fine-tuned previously [26, 27] using palmitic acid (92.5 mg) mixed with cholesteryl myristate (42.5 mg) as the lipid phase. In practice, RIF was added to the lipid phase at 1:3 RIF/lipid ratio, melted at 85°C, and emulsified in 10 mL Milli-Q water (highly pure water with a measured resistance of 18.2 MΩ cm −1 at 25°C, Millipore, USA) containing 100 mg P1, P2, P3, or P4 functionalizing agents as the aqueous phase by ultrasounds (14 output watts; Vibra-Cell, Sonics & Materials, Newtown, CT, USA) for 2 min, to obtain an oil-in-water emulsion. For comparing moisture adsorption and intracellular RIF data, SLNas named PA1 and NF-PA1, previously developed [27] , were prepared under the same conditions using 2.25% ST/MP blend at 1:2 ratio and 2.25% ST, respectively, as the emulsion aqueous phase. SLNas/SLS sample was also prepared by using 2.25% sodium lauryl sulfate as the emulsion aqueous phase for evaluating the mannosylation efficacy based on xray photoelectron spectroscopy data. For cytotoxicity study, unloaded SLNas (prepared under the same conditions in the absence of RIF) were also considered. For cell internalization, labeled SLNas were obtained by dissolving Nile Red (0.01%) in the melted palmitic acid. SLNas thus obtained proved to retain firmly the dye [29] . The emulsions were rapidly cooled in an ice bath under magnetic stirring for 15 min and the obtained nanoparticle suspensions, in aliquots of 5 mL, were purified in 300 mL water by dialysis (MWCO 12-14,000 Da) for 15 min, time period resulted adequate from preliminary studies to remove the nonencapsulated drug and the excess of surfactant. Then, the samples were diluted with water at 1:55 ratio, rapidly frozen at − 70°C in a dry ice/acetone cooling bath, and freeze-dried to obtain four final powder formulations named SLNas/P1, SLNas/P2, SLNas/P3, and SLNas/P4.
SLNas characterization
Morphology, size, and Z-potential SLNas morphology was evaluated by scanning electron microscopy (SEM, Nova NanoSEM 450, Fei, Eindhoven, The Netherlands) using TEM mode with STEM detector (30 kV). Carbon/copper TEM grids were soaked in a diluted SLNas water suspension and, after drying, coated with carbon under vacuum conditions (Carbon Coater, Balzers CED-010, Oerlikon Balzers, Balzers, Liechtenstein). The obtained images were analyzed by an image software (ImageJ, Java, Maryland, USA) to measure circularity parameters on at least 100 particles from three batches.
Size distribution of SLNas and polydispersity index (PDI) was assessed measuring the hydrodynamic diameter by dynamic light scattering (Zetasizer version 6.12, Malvern Instruments, Worcs, U.K.) equipped with a 4 mW He-Ne laser (633 nm) and a DTS software (Version 5.0). All the samples were dispersed in water for surface charge determination (Zpotential) and in DMEM with FBS for size and PDI, vortexed for 1 min, and sonicated for 3 min in ultrasonic bath (USC200TH, VWR Collection, VWR, Milan, Italy) at 37°C in order to obtain a better re-suspension. Particle size and PDI of all the samples, maintained for 6 months in a test tube inside dark glass vacuum desiccator at room temperature (25°C), were analyzed by the same methods. The reported values averaged the determinations on three batches.
Aerodynamic performance
Powder in vitro respirability was preliminarily assessed using fast screening impactor (FSI) (Copley Scientific, Nottingham, UK) and then next generation impactor (NGI) (Copley Scientific Ltd., Nottingham, UK). SLNas samples were loaded into a size 3 capsule (V-Caps Capsugel, Morristown, New Jersey, USA) and aerosolized using a RS01 device (IFR = 0.033 kPa0.5/LPM, Plastiape, Lecco, Italy). A flow rate of 60 L/min, capable of producing a pressure drop of 4 kPa over the inhaler, was set before each experiment by a Flow Meter DFM 2000 (Copley Scientific, Nottingham, UK). RS01 was activated and the vacuum applied for 4 s so that a volume of 4 L of air was drawn through the inhaler during the experiment. All the experiments were performed in triplicate.
FSI divides the particles emitted from the inhaler into two fractions, namely a coarse fraction and a fine fraction with aerodynamic size lower than 5 μm. The particles not captured in the coarse fraction collector (CFC) keep following the airstream and deposit in the fine fraction collector (FFC) where an A/E glass filter (76 mm, Pall Corporation, USA) captures all the particles. For each experiment, a single capsule loaded with about 10 mg of powder was aerosolized. The RS01 device and the filter were weighed before and after each actuation in order to determine the emitted dose (ED) and the drug deposited on the FFC. The respirable fraction (RF) was calculated by the formula:
where FFC is the amount of powder with size < 5 μm and LD the amount of powder loaded in the capsule.
Then, the most promising powders were characterized by NGI following the methodology recommended in the US and European pharmacopeia monographs [30, 31] . The NGI was assembled with a micro-orifice collector (MOC) for capturing particles smaller than the stage 7 cut-off diameter and connected to a VP1000S vacuum pump (Erweka GmbH, Heusenstamm, Germany). For each experiment, a single dose of RIF embedded in about 10 mg of SLNas was discharged into the NGI. The measurement of RIF deposited in the impactor allowed the calculation of deposition parameters. The metered dose (MD) is the mass of drug recovered quantified by HPLC and calculated by summing the drug recovered from the inhaler (device and capsule) and the impactor (induction port, pre-separator, stages 1 to 7, and MOC). The emitted dose (ED) is RIF amount leaving the device entering the impactor (induction port, stages 1 to 7, and MOC) quantified by HPLC. The mass median aerodynamic diameter (MMAD) was determined by plotting the cumulative percentage of mass less than the stated aerodynamic diameter for each stage on a probability scale versus aerodynamic diameter of the stage on a logarithmic scale. The fine particle dose (FPD) is the mass of drug < 5 μm calculated from log-probability plot and the fine particle fraction (FPF) is the ratio of the FPD to the ED.
Drug loading and encapsulation efficiency
SLNas drug loading (% w/w) was determined by HPLC analysis. The system consisted of two PU-2080 Plus pumps, an HG-980-30 solvent mixing module and a UV-2075 Plus UV-VIS detector; data were recorded and processed by Hercule Lite Chromatography Interface and Borwin Software, respectively (Jasco Corporation, Tokyo, Japan). Manual injection was performed by a Rheodyne 7725i injection valve (IDEX Corporation, Rohnert Park, CA, USA); the mobile phase was degassed during use by a solvent degasser (Degasys DG-1210, Uniflows Co., Ltd., Tokyo, Japan). Chromatographic analyses were performed on Purospher RP-18e column (125 × 4.0 mm; 5.0 μm) equipped with a Purospher guard column (4.0 × 4.0 mm; 5.0 μm) (Merck Darmstadt, Germany) with a mobile phase of (A) aqueous acetate buffer (pH 5.0; I = 0.02 M) and (B) methanol using the following gradient program: 0.0-5 min, isocratic at 60% (B); 5-10 min, linear gradient from 60 to 80% (B); 10 to 18 min, isocratic at 80% (B); 18 to 20 min, linear gradient from 80 to 60% (B). A pre-equilibration period of 15 min was used between each run. The flow rate was 0.9 mL/min and the column temperature was 30°C. The injection volume was 6.0 μL and the column eluates were monitored at 254 nm.
Working solutions at different RIF concentrations (n = 6; range: 12.8-51.2 μg/mL) were added with the IS solution and analyzed in triplicate; the peak-area ratio of analyte to IS (y) was plotted against the analyte concentration (x) to generate the calibration curve by the method of least squares using a weighed (1/x) linear regression model.
For SLNas samples, 10 mg aliquot was weighed in 10 mL volumetric flask and added with IS solution and methanol, heated at 50°C for 30 min and finally diluted (1:5) with methanol. The obtained samples were subjected to HPLC analysis in triplicate and RIF content was estimated through the calculated calibration curve. Encapsulation efficiency (EE%) values, expressed as the percentage of drug entrapped in SLNas (actual drug loading) compared to the initial amount of drug used in SLNas preparation (theoretical loading), were calculated.
Physical state of the components
Thermograms of SLNas samples and physical mixture prepared at the same drug/lipid ratio as SLNas were recorded by differential scanning calorimeter (DSC) (DSC-4, PerkinElmer, Norwalk, CT, USA) previously calibrated with indium. A heating rate of 20°C/min was employed over a temperature range of 30-300°C with nitrogen purging (30 mL/min). The analyses were performed in triplicate.
Moisture adsorption
All the samples (SLNas/P2, SLNas/P3, SLNas/P4, PA1, and NF-PA1) were weighed in a Petri dish and left in a drier under vacuum until reaching a constant weight value. The fully dried state of the samples was verified by means of thermogravimetric analysis (supplementary information). After predetermined time intervals in open air, the samples were weighed. The uptake of weight was considered equal to the water adsorption. The reported data were averaged on three determinations.
Assay of mannose derivatives on SLNas surface
The determination of the hydrophilic groups of mannose derivatives on SLNas surface was performed by x-ray photoelectron spectroscopy (XPS) analysis system 04-151 X-ray source (Physical Electronics, Chanhassen, MN, USA) and a hemispherical electron analyzer EA11 (Leybold Optics, Alzenau, Germany), using MgKα1,2 radiations (E = 1253.6 eV) and compared with data obtained from NF-PA1 sample. The spectra were recorded in fixed retardation ratio mode with 190 eV pass energy. The pressure in the sample analysis chamber was about 10 −1 Torr. Data acquisition was performed with the RBD AugerScan 2. High-resolution data were collected using pass energy of 50 eV in 0.1 eV steps. Spectra were analyzed for C1s peaks, in particular for C-O or C-OH bonds at 286.5 eVand for O1s peaks. In this latter case, it was possible to deconvolute the signals into two components, C=O at 531.8 eV and C-O or C-OH bonds at 533.1 eV. Curve fitting routines were performed using Igor Pro software. Signals were attributed on the basis of literature data [32] . Moreover, mannosylation efficacy was determined by the ratio between the C-O/C-OH peak values obtained from SLNas samples and that provided by SLNas/SLS sample used as a control.
In vitro drug release
In vitro RIF dissolution and release from SLNas samples were examined in sink conditions on exactly weighed samples (100 mg) by means of the dialysis membrane (MWCO 12-14,000 Da) method, in 30 mL of SLF under gently magnetic stirring at a temperature of 37.0 ± 0.2°C to reproduce stagnant lung conditions [33] . Sample solutions (1 mL) were withdrawn at fixed intervals for a time period of 6 h and the initial volume restored. RIF quantification was performed spectrophotometrically (Lambda 35; Perkin-Elmer, Norwalk, CT, USA) in triplicate at the wavelength of 475 nm.
Cell culture assay
J774 murine macrophage cell line, established from a reticulum cell sarcoma that arose in a female BALB/c mouse, was cultured as a monolayer in DMEM containing 2 mM L-glutamine, penicillin 100 UI/mL, 100 μg/mL streptomycin, NEAA 1×, and 10% FBS at 37°C in a humidified 5% CO 2 atmosphere. J774 cell line was selected as the most commonly used model to study the interaction with lung cells [34] .
Cytotoxicity test
J774 murine macrophage cell line was seeded at a density of 150,000 cells/well in 24-well tissue culture plates in complete DMEM to evaluate the cytotoxicity of both SLNas and bare mannosylated derivatives. Regarding SLNas samples, cells were incubated with 1 mL of loaded and unloaded SLNas suspension in complete medium (vortex mixing for 1 min and sonic bath at 37°C for 3 min) at 0.125, 0.25, 0.5, and 1.0 mg/mL particle dose for 6 h incubation time. Regarding mannosylated derivatives, cells were incubated with bare P1, P2, P3, and P4 (10, 50, 100, 200, 300, and 350 μg/mL) for 12 h incubation time. Cell viability was estimated by colorimetric 3-(4,5 di-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test [35] . Intracellular RIF determination J774 cells were plated in 100 mm Petri dish (2,000,000 cells) and incubated with SLNas suspensions (0.25 mg/mL) or with the corresponding amounts of pure RIF (15.40, 26 .00, and 33.00 μg/mL) for 30 min and 1, 3, 6, 12 h. After incubation, cells were washed with PBS to remove the possible SLNas and RIF adherent on cell membrane and then collected by gentle scraping. PBS (5 mL) was added to suspended cells and transferred in tubes. After cell centrifugation for 10 min at 5000 rpm and 25°C, supernatant was removed. RIF embedded inside cells was extracted by methanol (1 mL) and drug concentration was determined spectrophotometrically at 475 nm and expressed as RIF percentage on the actual drug loading level of each sample batch. Reported data were averaged on three determinations.
MR inhibition study
J774 cells were treated for 2 h with 25 mM D-mannose, washed with PBS to remove free D-mannose, and incubated with SLNas/P2 (0.25 mg/mL) for 1 h. Then, cells were handled as described in the previous section for the intracellular RIF determination. As a control, intracellular RIF amounts from NF-PA1 sample after 1 h incubation were determined on cells with or without D-mannose treatment. Reported data were averaged on three determinations.
Statistical analysis
Data obtained were evaluated statistically using one-way analysis of variance (ANOVA). Significance was indicated by p < 0 . 0 5 ( * p < 0 . 0 5 ; * * p < 0 . 0 1 ; * * * p < 0 . 0 0 5 ; ****p < 0.001).
Results and discussion
Inhaled carriers for AM targeting require the ability to be transported both to the alveolar region and into AM. Novel molecules bearing mannose residues were considered in the perspective to achieve a greater powder protection from particle cohesion aiming to improve the respirability performance compared to that previously obtained using MP [27] . Indeed, these newly synthesized molecules include a more hydrophobic tail providing reasonably a more robust anchoring within the lipid matrix compared with MP. Moreover, these innovative mannose derivatives were found suitable for the emulsion stabilization having a dual role of functionalizing agents and surfactants. The chemical structures of P1, P2, P3, and P4 molecules are reported in Fig. 1 . The molecules are constituted by a mannose residue conjugated to an array of saturated fatty acids (carbon chain between 8 and 16 atoms) through a short linker at the anomeric alpha hydroxyl group. The fatty acids were selected with the aim of providing suitable hydrophilic/lipophilic balance (HLB) values to stabilize and decorate the surface of the particles during their production. The synthesis ease (supplementary information) makes these compounds adequate for a scale-up procedure. For SLNas sample development, a blend of palmitic acid and cholesteryl myristate was selected as the lipid matrix owing to meltprocessable characteristics and low cytotoxicity [27, 36, 37] . SLNas were loaded with RIF, a first-line anti-TB drug, and surface functionalized by P1, P2, P3, and P4 molecules producing SLNas/P1, SLNas/P2, SLNas/P3, and SLNas/P4 samples, respectively, in order to obtain final respirable powders for macrophage active targeting.
SLNas characterization
The efficiency of an inhaled powder formulation is dependent upon particle geometrical parameters, which concur to the powder respirability as well as macrophage uptake. Indeed, particle shape and surface morphology, even if combined with the size, can play a relevant role in powder aerodynamic performance [38] . Most commonly used particles for DPI device have irregular shapes. In vitro inhalation studies have indicated that elongated [39, 40] , needle-like [41] , porous and wrinkled [18] , as well as thin flaky shape [42] improve lung deposition properties owing to reduced particle interactions [43] . Concerning macrophage phagocytosis, particle shape has been reported affecting cell uptake mechanism or rate even if roundness would appear to be favored compared to elongated or filamentous shapes [38, 44, 45] . All the SLNas samples exhibited micro-aggregates of wellformed nanoparticles having a round flaky shape with a corrugated surface without notable differences among the samples as highlighted by circularity values from 0.56 to 0.63 (p > 0.05), where the spherical shape is characterized by a value of 1 (Fig. 2, Table 1 ).
Particle size of the samples expressed as median hydrodynamic diameter of the main class (> 85%) was in the range from about 0.4 to 1.5 μm, adequate for alveolar epithelium deposition and AM endocytosis [38] , with PDI values higher than 0.3 owing to the presence of other minor populations in the range of 2-5 μm (< 15%). Original SLNas dimensional properties (size and PDI) were found stable for at least 6 months without significant differences (p < 0.05). Due to both SLNas lipids and mannose derivatives, the surface charge of all the samples was negative (from − 30.10 to − 49.73 mV). Macrophage uptake extent and rate are known for being directly related to particle net charge magnitude with physiological compatibility of negatively surface charges greater than positively ones [38] . Moreover, particle localization within lysosomes, in which Mycobacterium tuberculosis survives, was found favored by particles having negative surfaces compared to those bearing positive charges [46] [47] [48] .
Although nanoparticles bear the potential of improved pulmonary therapy, in terms of increased AM uptake, their delivery to the lungs is challenging. Nanosize gives to particles poor possibility to deposit into the lung due the high tendency to be exhaled [49] . Therefore, the undried lipid nanoparticles were transformed in a microsized powder (SLNas) by freezedried and a preliminary respirability screening step was performed to determine the values of ED and RF using FSI equipment (Table 1 ). All the samples provided ED values > 78% and RF values > 40%, which are considered favorable and in agreement with the respirability values usually obtained by DPI products [50] , with the exception of SLNas/P1 (RF = 17.20 ± 2.00%). Indeed, P1 functionalizing agent, having the shortest fatty acid chain, would provide a weak anchoring on the particle surface increasing the aggregation phenomenon and the aggregate stability unevenly. This finding would cause aggregate multimodal size distribution, as highlighted by the highest size and PDI values of SLNas/P1.
Besides these intrinsic properties related to the respirability performance, inhaled particulate carriers require sufficient drug payload to achieve a therapeutic effect in function of a feasible administration dose inside DPI [51] . The obtained RIF loading levels % and EE% values ranged from 7.38 to 14.12% and from 29.52 to 56.48%, respectively, with the lowest values ascribed to SLNas/P1 ( Table 1 ). The loaded RIF was in almost amorphous state within SLNas matrices as demonstrated by DSC analysis (Fig. 3) . Indeed, RIF thermal event at about 260°C was detectable only in the physical mixture. Contrarily, the endothermic peaks of palmitic acid and cholesteryl myristate, recorded at their typical melting points ranging from 50 to 70°C, were observed in both SLNas and physical mixture thermograms. The least ability to incorporate the drug and the inadequate respirability of SLNas/P1 sample implied its discard from the further tests.
The actual presence of mannose on the particle surface of respirable SLNas/P2, SLNas/P3, and SLNas/P4 was evaluated by means of moisture adsorption measurements and XPS analysis. In our previous research, surface functionalized SLNas (PA1) were produced using the same lipid phase and a blend of sodium taurocholate/methyl α-D-mannopyranoside (MP) as aqueous phase, in comparison with non-functionalized SLNas (NF-PA1) prepared without MP. Mannosylation determined a massive reduction in respirability probably because of both moisture adsorption on mannose residues and high adhesion forces among mannose hydroxyl groups that could make the powder cohesive [27] . Indeed, PA1 moisture adsorption was found greater than NF-PA1 (p < 0.001) confirming such a hypothesis. SLNas functionalized using the newly synthesized compounds showed moisture adsorption values comparable to that of NF-PA1 sample (p > 0.05) although they contain mannose residues on their surface (Fig. 4) . This finding could indicate a different arrangement of the functionalizing agents on the particle surface decreasing moisture sensitivity. XPS analysis (Table 2) shows that mannosylated SLNas samples exhibited a greater component concerning C-OH bonds compared to that of both NF-PA1, bearing OH-groups belonging to sodium taurocholate, and SLNas/SLS sample obtained by a surfactant devoid of hydroxyl groups. Among the functionalized samples, SLNas/P4 exhibited the highest level of C-OH component (3.7 mannosylation efficacy) with respect to SLNas/P2 and SLNas/P3 (2.4 and 1.8 mannosylation efficacy, respectively), probably due to the longer lipophilic chain that allows a better anchoring of the mannose derivative on the particle surface. Moreover, nitrogen atoms, belonging exclusively to mannose derivatives, were detected only in mannosylated SLNas, confirming the actual presence of these moieties on the particle surface. The preliminary aerodynamic performances of mannosylated SLNas samples were confirmed by NGI analysis which allows MMAD calculation and a more accurate determination of the aerodynamic particle size distribution (Fig. 5 ). All the samples showed an optimal dose emission by the device, with a retention < 10% (Table 3) . It has been recently revealed that the capsule motion under inhalation airflow essentially governs the powder emission and the spinning rotation is more efficient compared to the axially vibration [52] . Although no MMAD value was less than 5 μm, SLNas/P3 exhibited the highest particle de-aggregation leading to a FPF value of 49.67%. Indeed, the aerodynamic distribution of this powder inside the impactor showed a higher deposition in all the impactor stages collecting the fine aerosol fraction (stages 4 to 6), compared with the other two formulations. Moreover, for SLNas/P3 powder, the deposition in the MOC, capturing particle with size less than 0.37 μm, reached 8%. On the contrary, SLNas/P4 resulted the worst by considering the highest MMAD (6.98 μm) and the amount of powder over the stage 1 suggesting the presence of strong and cohesive agglomerates after aerosolization. The existence of an inverse relationship between the amount of mannose hydroxyl groups on the particle surface is notable, as revealed by XPS analysis, and FPF values denoting the fundamental role of surface chemical properties on powder wettability, inter-particle adhesion, deaggregation, and consequently respirability [53, 54] . While respirability is a prerequisite for SLNas deposition onto alveolar region, on the other hand, the carrier would be able to retain mostly the drug upon contact with lung fluids until its entry into AM. In vitro drug release from SLNas in comparison with RIF dissolution is shown in Fig. 6 . Unlike dissolution of the pure drug that completed in about 1 h, RIF release from SLNas was modulated by the lipid matrix. Drug release rate from SLNas increased in the order SLNas/P4 < SLNas/P3 < SLNas/P2, reaching RIF amounts from about 26 to 52% in 6 h. This finding could be related to the increase of the functionalizing agent chain length increasing RIF retaining capability. Indeed, the longer hydrophobic chain could induce a closer arrangement of the functionalizing agent within the lipid phase providing a firmer SLNas matrix [55] . Moreover, considering that 50-75% of the particles are taken up by AM in 2-3 h [44] , the prevention of drug spreading over the lung fluid before the occurrence of SLNas uptake by AM could be reasonably expected. Following AM phagocytosis, lipid materials are known to undergo enzymatic degradation inside macrophages allowing the intracellular drug delivery and antibacterial activity [56] .
Cell culture assays
To support the goal of achieving AM targeting and effective RIF concentration at the site of infection, SLNas ability to interact with macrophages was established on J774 cell line, a murine macrophage model. The proper amount of SLNas to be used for the internalization study was selected from the results provided by the cytotoxicity assay based on MTT test. Moreover, the newly synthesized compounds P2, P3, and P4 were assessed for their possible cytotoxicity that was found dose-dependent with IC50 values of 85.95 ± 5.14 μg/mL, 46.91 ± 3.39 μg/mL, and 93.66 ± 4.15 μg/mL, respectively. This expected finding is consistent with the general surfactant cytotoxicity related to cell membrane destabilization [57] . Nevertheless, such a drawback may be reasonably disregarded by considering the surfactant monolayer adsorbed at SLNas surface. Concerning SLNas, the test was carried out on increasing sample amounts (from 0.125 to 1 mg/mL) in comparison with unloaded SLNas. MTT test results, expressed as cell viability in function of the sample amount at 6 h incubation, demonstrated a dosedependent cytotoxicity (Fig. 7) . Insignificant differences (p > 0.05) in cell viability values were found between loaded and unloaded samples, with the exception of SLNas/P3 sample at 0.5 mg/mL dose, highlighting the non-cytotoxicity of RIF dose as previously determined [27] . Since SLNas components are known as generally Table 3 Aerodynamic parameters of SLNas: metered dose (MD), emitted dose (ED), mass median aerodynamic diameter (MMAD), fine particle dose (FPD), and fine particle fraction (FPF). Data expressed were related to 1 mg of RIF embedded in 7. recognized as safe (GRAS) with low cytotoxicity at the concentrations used, the dose-dependent cytotoxicity of both unloaded and loaded SLNas as well as the nonlinear behavior of SLNas/P3 could be attributed to a more considerable and non-uniform particle aggregation leading to a decrease in cell activity even to death [58] . The assessment of SLNas macrophage internalization was performed on 0.25 mg/mL SLNas amount by means of flow cytometry and confocal microscopy. The results of the flow cytometry analysis on J774 cell line incubated with SLNas samples at different times of treatments are shown in Fig. 8 . The mean cell fluorescence percentage of all the analyzed samples showed a time-dependent increase. In particular, SLNas/P4 sample provided significantly higher fluorescence value already at 15 min incubation, then achieving about 35% fluorescence at 12 h. The greatest internalization ability of SLNas/P4 may be due to the highest presence of mannose derivative as highlighted by XPS analysis. Furthermore, it was observed that J774 cells incubated for 6 and 12 h detached from the adherent surface confirming the macrophage activation probably caused by a change of cell phenotype [59] .
In order to clarify SLNas cellular location, J774 cells incubated for 6 h with Nile Red labeled SLNas/P2, SLNas/P3, and SLNas/P4 samples after nuclei (blue) and lysosome (green) staining were observed by confocal microscopy (Fig. 9) . The images revealed overlapped strong red and green fluorescence spots inside cell cytoplasm, regardless of the sample. This finding may reasonably indicate the presence of all SLNas samples within lysosomal organelles.
To verify the achievement of effective RIF concentration inside cells, intramacrophagic drug following incubation with SLNas compared with pure RIF in solution at different times of treatments was detected (Fig. 10) . The graph clearly indicated relevant and significant increases in drug content within macrophages provided by SLNas compared to pure RIF solution, regardless of RIF concentration (p < 0.01). This confirms both RIF difficulty to diffuse across macrophage membranes and SLNas efficacy to transport the drug into macrophages. Following incubation with pure RIF solution, the reduced intracellular RIF with the increase of its concentration could be attributed to the external cell membrane saturation by the drug during the first step of the phagocytosis process (p < 0.05) [60] . In addition, the intracellular RIF concentration following incubation with SLNas increased (p < 0.05) up to 3 h and then gradually decreased at 6 and 12 h reasonably due to drug degradation caused by intracellular metabolism (p < 0.05).
The actual occurrence of an active targeting involving specific binding of SLNas to macrophage MR was evaluated on J774 cells previously treated with D-mannose with the aim to saturate MR [61, 62] . Cells were incubated with SLNas/P2 sample for 1 h, selected among the samples and the incubation times owing to the highest RIF intracellular level achieved on culture without D-mannose treatment. The assay carried out in the presence of D-mannose resulted in a marked reduction of RIF intracellular concentration (p < 0.005). Conversely, MR saturation by D-mannose did not affect RIF intramacrophagic entry when transported by non-mannosylated SLNas (NF-PA1 sample), used as a control (p > 0.05) (Fig. 11) . These findings implicate MR as relevant contributors in the overall macrophage phagocytic process including a combination of passive and active targeting. Given that comparable RIF intracellular Fig. 7 SLNas cytotoxicity on J774 cell line: a unloaded SLNas; b loaded SLNas (dotted line as the control, i.e., the untreated cells). Statistical significance levels are indicated as *p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001 
Conclusions
The urgency to effectively treat pulmonary TB, one of the top 9 causes of death worldwide, was addressed by the development of inhalable lipid-based vehicles for the delivery of drugs directly to the infected tissue. This research exploited the targeting to macrophages of RIF loaded into SLNas emitted by DPI device. The results demonstrated the effectiveness of the carrier surfacedecorated with mannose derivatives acting as surfactants in terms of both respirability and uptake by macrophages involving mannose receptors. In detail, the level of mannose residues on SLNas surface was found to play a reverse role on macrophage internalization and respirability performance, even if a proper compromise between these two SLNas abilities is achievable. Moreover, considering the use of an approved drug and biomaterials already accepted by regulators as well as organic solvent avoidance, the technology here described can be classified as a green process and suitable for scale-up development. 
